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There are approximately one million new cases of col-
orectal cancer (CRC) per year worldwide, with sub-
stantial associated morbidity and mortality. The long 
natural history of colorectal neoplasia affords the op-
portunity to use preventive measures to improve sur-
vival in this disease. Currently screening for ad-
enomatous polyps and early-stage cancers is the best 
methodology for improving survival. The increasing 
knowledge of CRC pathogenesis and its natural his-
tory is allowing the development of new tools to iden-
tify patients who will benefit most from colon cancer 
screening and the defining of appropriate surveillance 
intervals. The guidelines for screening for colorectal 
neoplasia have recently been substantially revised by 
several organizations based on developing tech-
nologies and a growing body of data on the efficacy 
of CRC screening. (Gut and Liver 2009;3:69-80)
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INTRODUCTION
  Cancers of the colon and rectum (CRC) are a major 
cause of cancer-associated morbidity and mortality 
world-wide. CRC is the fourth most common newly diag-
nosed internal cancer overall in the United States, after 
cancers of the lung, prostate, and breast, and currently 
constitutes 10% of new cancers in both men and women. 
In 2008, there were an estimated 149,000 new CRC cases 
in the United States and 51,000 related deaths (a rate 
second only to that of lung cancer).
1 Globally, CRC is the 
f o u r t h  m o s t  c o m m o n  c a n c e r  i n  m e n  a n d  t h e  t h i r d  m o s t  
common in women, accounting for approximately one 
million new cases per year.
2 While there is at least a 
25-fold variation in the occurrence of CRC worldwide, 
many countries where CRC mortality was previously low 
have reported substantial increases during the past 
decade.
3 CRC has become one of the most common can-
cers in a number of Asian countries, for example. Despite 
evidence that 5-year survival is 90% when CRC is diag-
nosed at an early stage, less than half of cases are diag-
nosed when the cancer is still localized.
  Rapid growth of knowledge about the molecular and bi-
ologic characteristics of epithelial cancers has provided 
useful insights into the pathogenesis of colonic neoplasia. 
New insights also have been gained in regard to primary 
prevention. Because CRC arises over long periods as the 
result of interactions between genetic predisposition and 
environmental insults, it has become possible to identify 
pre-neoplastic and early neoplastic lesions with the hope 
of improving survival rates. More complete knowledge of 
CRC pathogenesis and its natural history, especially in 
high-risk groups, is allowing the development of new 
tools to identify those who will benefit most from colon 
cancer screening and in defining proper surveillance in-
tervals. During the past year guidelines for screening for 
colorectal neoplasia have been substantially revised by 
several organizations based on developing technologies, 
and a growing body of data regarding the efficacy of CRC 
screening. This review will focus on evolving concepts 
and an evidence-based approach to CRC screening.
PRINICIPLES OF SCREENING
  Cancer prevention has been traditionally categorized as 
primary or secondary. Primary prevention refers to the 
identification of genetic, biologic, and environmental fac-70   Gut and Liver, Vol. 3, No. 2, June 2009
tors that are etiologic or pathogenetic and subsequent al-
teration of their effects on tumor development.
4 Although 
several areas of study have been identified that may lead 
t o  p r i m a r y  p r e v e n t i o n  o f  C R C ,  a v a i l a b l e  d a t a  d o  n o t  y e t  
provide a firm basis for the practical application of pri-
mary preventive measures in most cases. The goal of sec-
ondary prevention (which includes screening) is to identi-
fy existing preneoplastic and early neoplastic lesions and 
to treat them thoroughly and expeditiously. The assump-
tion is that early detection improves prognosis. Screening 
an asymptomatic population for any disease is worthwhile 
if the disease represents a major health problem, effective 
therapy is available if the disease is found, a sensitive and 
specific screening test is available that is readily accept-
able to patients and physicians, and the screening test is 
cost-effective.
  The long natural history of colonic neoplasia, and mu-
cosal progression through defined phenotypic changes 
(the adenoma to carcinoma pathway) associated with 
identifiable genetic alterations fundamental to this proc-
ess, makes CRC feasible. The challenge has been to de-
velop effective, easily administered, and cost-effective 
screening tests for the disease. Current evidence strongly 
suggests that screening for CRC reduces related mortality. 
Direct evidence for this is available from prospective trials 
of fecal occult blood testing (FOBT),
5 indirectly for colo-
noscopy and polypectomy (versus historical controls) 
from the National Polyp Study
6 and from a recent case- 
control trial.
7 These findings have resulted in recommen-
dation by numerous organizations, including the evidence- 
based United States Preventive Services Task Force 
(USPSTF), that screening for CRC should be performed 
in all persons aged 50 years to 75 years (see below). 
  Previous studies reviewed by the USPSTF indicated that 
C R C  s c r e e n i n g  i s  l i k e l y  t o  b e  c o s t  e f f e c t i v e  ( ＜$30,000 
per additional year of life gained in the United States) re-
gardless of the strategy chosen. A more recent decision 
analysis comm issioned by the USPSTF used m icrosimula-
tion models from the Cancer Intervention and Surveilance 
Modeling Network to assess life-years gained and colono-
scopy requirements for screening strategies.
8 This group 
concluded that their findings support colorectal cancer 
screening with colonoscopy every 10 years, annual screen-
ing with a sensitive FOBT, or flexible sigmoidoscopy ev-
ery 5 years with a midinterval FOBT from age 50 to 75 
years. This was part of the basis for recent modifications 
to the USPSTF guidelines.
  The willingness of both patients and physicians to com-
ply with recommendations for screening programs has a 
major impact on the effectiveness (and cost effectiveness) 
of CRC screening. Compliance by both the population at 
large and health care providers has historically has been 
poor, and interventions to increase screening adherence 
have been disappointing. The key questions of “who, 
how, and how often” to screen remain a source of debate. 
GUIDELINES
  In 2008 new guidelines on screening and surveillance 
for early detection of colorectal cancer and adenomatous 
polyps was issued jointly by the American Cancer Society 
and the US Multi-Society Task Force on Colorectal Can-
cer, and the American College of Radiology (Table 1).
9 
This update of previous guidelines is notable in that it 
grouped screening tests into those that primarily detect 
cancer (annual FOBT including those that are guaiac- 
based or immunochemical tests, and stool DNA tests in-
terval not specified), and those that can detect early can-
cer and adenomatous polyps (flexible sigmoidoscopy every 
5 years, colonoscopy every 10 years, double contrast ba-
rium enema every 5 years, or Computed tomography 
[CT] colonography every 5 years). In November 2008 the 
USPSTF also issued updated guidelines (Table 1).
10 Based 
on a targeted evidence-based review and a decision ana-
lytic modeling analysis the USPSTF recommended screen-
ing of average risk individuals age 50 to 75 years with 
high sensitivity FOBT annually, sigmoidoscopy every 5 
years plus FOBT every 3 years, or colonoscopy every 10 
years. Notably the USPSTF indicated that while the bene-
fits of screening outweigh the potential harms for 50- to 
75-year-olds, the likelihood that detection and early inter-
vention will yield a mortality benefit declines after age 75 
because of the long average time between adenoma devel-
opment and cancer diagnosis. Routine screening was 
therefore not recommended for adults age 76 to 85 years, 
and screening was not recommended at all in adults older 
than 85 years of age. These guidelines also indicated that 
for all populations there is insufficient evidence to assess 
the benefits and harms of screening with CT colonog-
raphy or fecal DNA testing.
  In 2008 an Asia Pacific Working Group on Colorectal 
Cancer published consensus recommendations for color-
ectal cancer screening.
11 This group concluded that the in-
cidence, anatomical distribution and mortality of CRC 
among Asian populations are not different compared with 
Western countries. They concluded that screening for col-
orectal cancer should be started at age 50 years. FOBT 
(guaiac-based and immunochemical), flexible sigmoido-
scopy and colonoscopy were recommended for CRC 
screening. Double contrast barium enema and CT colo-
nography are not preferred. In resource-limited countries 
FOBT is the first choice for CRC screening. 
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Table 1. Guidelines for Screening Average Risk Individuals for Colorectal Cancer
Screening tool
U.S. Preventive Services
Task Force*
American Cancer Society, US Multi 
Society Task Force, American 
College of Radiology Joint Guidelines
†
High sensitivity FOBT 
 (guaiac-based or immunochemical)
Flexible sigmoidoscopy
Colonoscopy
Double-contrast barium enema
Computed tomographic colonography
Stool DNA testing
Recommended annually as an option
Recommended q 5 yr+high sensitivity
 FOBT q 3 yr as an option
Recommended q 10 yr as an option
Not recommended
Not recommended
Not recommended
Recommended annually as an option
Recommended q 5 yr as an option
Recommended q 10 yr as an option
Recommended q 5 yr as an option
Recommended q 5 yr as an option
Recommended (interval uncertain)
FOBT, fecal occult blood test.
*U.S. Preventive Services Task Force. Screening for colorectal cancer: US Preventative Services Task Force Recommendation 
Statement. Ann Intern Med 2008;149:627-637. The US Preventative Services Task Force recommends screening for adults age 50 
to 75 years. Screening for adults age 76 to 85 is not routinely recommended, and for adults older than 85 years screening is not 
recommended. 
†
Levin B, Lieberman DA, McFarland B, et al. Screening and surveilance for the early detection of colorectal cancer and adenomatous 
polyps 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the 
American College of Radiology. CA Cancer J Clin 2008;58:130-160. Testing options are divided into those that detect adenomatous 
polyps and cancer (flexible sigmoidoscopy, colonoscopy, double-contrast barium enema, computed tomographic colonography), and 
those that primarily detect cancer (FOBT, stool DNA testing).
  In a recent survey conducted by the International Di-
gestive cancer alliance (IDEC) across Europe, 21 of 39 
countries have reported national screening guidelines pro-
moted by medical and professional organizations.
12
  Although each of the options for CRC screening has in-
herent characteristics related to accuracy, prevention, po-
tential costs, and risks, the concept has long been that 
any one of the tests is better than no test at all. Multiple 
options can be confusing, however, to both patients and 
physicians. Furthermore, the test options are not of equal 
efficacy, and such guidelines may lead to coverage of sub-
optimal testing by insurance payers or health care agen-
cies.
SCREENING TECHNIQUES
1. Fecal occult blood testing
  Qualitative chromogen tests, which rely on the oxida-
tive conversion of a colorless compound to a colored one 
in the presence of the pseudoperoxidase activity of hemo-
globin, have been standardized employing guaiac-impreg-
nated paper and developing solutions (hydrogen peroxide 
in denatured alcohol) and have been widely studied and 
utilized clinically (e.g., Hemoccult, Hemoccult II). These 
tests are available commercially, convenient, and inex-
pensive, however, their effectiveness in detecting occult 
blood in the stool depends on the degree of fecal hydra-
tion (increases sensitivity), amount of hemoglobin degra-
d a t i o n  d u r i n g  s t o r a g e  o r  b y  f e c a l  f l o r a  ( d e c r e a s e s  s e n s i -
tivity), and the absence of interfering substances that can 
either enhance or inhibit oxidation of the indicator dye. 
Dietary components may also lead to false positive tests.
  Mortality data are available from the Minnesota Study, 
a randomized, controlled trial that has provided the best 
evidence for the effectiveness of screening with FOBT.
13,14
  After 13 years of follow-up, data indicate a 33% reduc-
tion in CRC-associated mortality with annual screening 
but an insignificant reduction of approximately 5% with 
biannual screening. Approximately 80% of samples were 
r e h y d r a t e d ,  y i e l d i n g  a  h i g h  p o s i t i v i t y  r a t e  o f  9 . 8 %  ( c o m -
pared with 2.4% for nonhydrated slides). This resulted in 
a 38% rate of colonoscopy, leading some to suggest that 
a substantial portion of the mortality reduction resulted 
from chance detection through colonoscopy of non-
bleeding cancers. This challenge has been refuted by the 
investigators, w ho find that only 6%  to 11%  of the m or-
tality reduction was explained by chance detection. 
Cumulative 18-year CRC mortality remained 33% lower 
in the group screened annually with FOBT than in the 
control group. A group tested with biennial screening 
now demonstrated a 21% lower CRC mortality than did 
the control group. Other randomized studies reported 
similar results.
5 Data from Funen, Denmark, suggested an 
18% decrease in CRC mortality associated with FOBT, 
and data from Nottingham, UK, also indicate a 15% re-
duction in mortality during follow-up. Data from a New 
York study suggested a 43% reduction in mortality in the 
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so demonstrated a reduction in CRC mortality with bien-
nial FOBT screening compared with a control population 
(mortality ratio, 0.84; 95% confidence interval [CI], 0.71- 
0.99) in 11 years of follow-up; reduction is mortality was 
more pronounced in compliant individuals (mortality ra-
tio, 0.67; 95% confidence interval, 0.56-0.81). Updated 
screening data for CRC using FOBT (Hemoccult) has re-
cently been reviewed by the Cochrane Collaboration.
5 
Data is presented for 11.7 years follow up from Notting-
ham, 17 years from Funen, 15.5 years fro Goteborg and 
18 years from Minnesota. Combined results from these 
four randomized controlled trials showed that participants 
allocated to screening had a 16% reduction in the relative 
risk of CRC-related mortality (RR 0.85, CI 0.78-0.90). In 
the 3 studies that used biennial screening, there was a 
15% reduction (RR 0.85, CI 0.78-0.92) in CRC mortality. 
When adjusted for screening attendance in the individual 
studies, there was a 25% relative risk reduction in mor-
tality (RR 0.75, CI 0.66-0.84) for those attending at least 
one round of screening using FOBT.
    Methods that may decrease the false-positive FOBT 
rates while maintaining or increasing sensitivity currently 
are being refined and compared for efficiency with He-
moccult-type slide tests. Fecal immunochemical tests 
(FITs) are designed to detect human globin and are not 
affected by diet or drugs. One FIT, HemeSelect, showed 
good performance characteristics compared with standard 
heme-based FOBT tests in early studies and was used in 
a combination test to confirm positive Hemoccult Sensa 
(a sensitive guaiac-based test similar to Hemoccult) in a 
large managed care setting. More recently, a FIT using a 
brush-based sampling technique and an immunogold 
membrane, which uses a dual antibody system specific for 
human hemoblobin, has undergone initial evaluation. 
Strategies that use an immunochemical-based FOBT have 
been shown to be cost-effective when used for colorectal 
cancer screening in Japan. Quantitative immunochemical 
FOBT has been shown to have good sensitivity and spe-
cificity for detection of clinically significant neoplasia in 
recent studies of asymptomatic and symptomatic indi-
viduals,
15,16 but test performance in prospective screening 
programs has been less well studied. Fecal immunochem-
ical tests have, however, been included in recent screen-
ing guidelines as an alternative to guaiac-based tests (see 
above).
2. Proctosigmoidoscopy
  The benefit of proctosigmoidoscopy in screening pro-
grams for CRC was suggested by several uncontrolled 
studies that used rigid proctosigmoidoscopy. Those stud-
ies suggested that proctosigmoidoscopy in asymptomatic 
average-risk persons might detect early-stage cancers and 
that detection and removal of adenomas could result in a 
lower than expected frequency of rectosigmoid cancers in 
the screened population.
  Two case-control studies provided strong evidence that 
sigmoidoscopy can reduce CRC mortality. A study from 
the Kaiser-Permanente Medical Care Program
17 compared 
261 members who died of cancer of the rectum or distal 
colon with 868 age- and sex-matched control subjects. 
Only 8.8% of case subjects had undergone screening by 
rigid sigmoidoscopy, compared with 24.2% of controls. 
Rigid sigmoidoscopy had no effect on mortality in anoth-
er group whose lesions were beyond the reach of the 
sigmoidoscope. Furthermore, the beneficial effect of sig-
moidoscopy extended 10 years. This and a second case- 
control study indicate that sigmoidoscopy can result in a 
70% to 80% reduction in mortality from cancers within 
reach of the sigmoidoscope. Because approximately 50% 
of all CRCs can be detected using the 60-cm flexible sig-
moidoscope these data suggest that periodic sigmoido-
scopic screening could reduce overall CRC-related mortal-
ity by about one third. Because the flexible sigmoidoscope 
is superior to rigid instruments in detecting lesions, the 
flexible sigmoidoscope has replaced the rigid sigmoido-
scope for CRC screening. A case-control study using FS 
and polypectomy demonstrated a 60% reduction in colon 
cancer incidence associated with this procedure. Rando-
mized, controlled trials are now underway to measure the 
effect of screening with FS on CRC mortality.
18,19 The 
Prostate, Lung, Colon and Ovarian cancer Screening Trial 
( P L C O )  s p o n s o r e d  b y  t h e  U S  N a t i o n a l  C a n c e r  I n s t i t u t e s  
has enrolled 155,000 individuals in a recent prospective, 
randomized trial that compares FS to a usual-care control 
group.
18,20 Follow-up is planned through 2,015 with can-
cer-related mortality as the major end point. The UK 
Flexible Sigmoidoscopy Screening Trial,
21 is a randomized 
trial examining the hypothesis that a single flexible sig-
moidoscopy screening offered at approximately age 60 
years can lower the incidence and mortality of colorectal 
cancer.
3. Colonoscopy, barium enema, and CT colonog-
raphy
  Colonoscopy may well be the most effective tool for 
CRC screening, but data from prospective, randomized 
trials are lacking. The National Polyp Study of poly-
pectomy and surveillance strongly suggested a reduction 
in CRC mortality as the result of removing adenomatous 
polyps compared to historic reference populations.
6 A re-
cent Canadian population based study compared the risk 
of developing colorectal cancer after a negative colono- 
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Fig. 1. CT colonography (“virtu-
al colonoscopy”). (A) Two-di-
mensional CT image of an an-
nular CRC. (B) Three-dimensio-
nal reconstruction of image in 
A. (C) Large sessile colon polyp 
evident in colonoscopy. (D) 
Three-dimensional image of le-
sion in C obtained by CT colo-
nography.
scopy in all Ontario residents with a history of a com-
plete negative colonoscopy with controls consisting of the 
Ontario population without a history of colonoscopy.
22 In 
the negative colonoscopy cohort, the relative risk of distal 
colorectal cancer was significantly lower than the control 
group in each of the 14 years of follow up, while the rel-
ative risk for proximal colorectal cancer was significantly 
lower mainly during the last 7 years of follow up. A sec-
ond Canadian case-control study demonstrated that com-
plete colonoscopy was also associated with fewer deaths 
from left-sided colorectal cancer, but not from right-sided 
cancer.
7 These recent findings are of interest in light of 
arguments that colonoscopy is preferable to sigmoido-
scopy, because there may be a substantial incidence of 
proximal colonic cancers and advanced adenomas beyond 
the reach of the sigmoidoscope. Some of these individuals 
may not have distal findings on sigmoidoscopy that 
would trigger a subsequent colonoscopy. Two trials
23,24 
suggested that approximately 50% of individuals with ad-
vanced proximal neoplasms (adenoma ＞1 cm; adenoma 
w i t h  v i l l o u s  f e a t u r e s  o r  d y s p l a s i a ;  c a n c e r )  h a v e  n o  d i s t a l  
neoplasms. Less than 2% of those who did not have dis-
tal neoplasms, however, had an advanced proximal le-
sion.
23 Given the need for colonoscopic follow-up, should 
FOBT or sigmoidoscopy be positive, colonoscopy may al-
so be cost-effective.
25
  A decision analysis commissioned by the USPSTF sup-
ports colonoscopy every 10 years as a screening option 
measured in life-years gained (see above).
  High contrast endoscopy using dye or stain solutions 
combined with colonoscopy (chromoendoscopy), or high 
resolution optical methods (e.g., narrow band imaging, la-
sar confocal endoscopy) has been suggested as a means of 
identifying lesions in high risk groups or as an adjunct to 
colonosocopy where flat lesions (so called “flat adeno-
mas”) are suspected. Recent evidence suggests that flat or 
depressed neoplasms are more common than previously 
appreciated, and carry a high relative risk of containing in 
situ or invasive carcinoma.
26
  Air contrast barium enema (ACBE) has been included 
as an option in a variety of screening guidelines. No stud-
ies, however, have directly addressed the effectiveness of 
barium enema for colon cancer screening. Several studies 
have indicated that the sensitivity of ACBE is less than 
that of colonoscopy,
27 especially for detecting lesions less 
than 1 cm. A recent population based study
28 suggested 
that if a cancer is present, there is approximately a one in 
f i v e  c h a n c e  t h a t  i t  w i l l  b e  m i s s e d  b y  A C B E .
  CT colonography, or “virtual” colonoscopy, involves the 
use of helical CT to generate high-resolution, two-dimen-
sional images of the abdomen and pelvis. Three-dimen-
sional images of the colon can be reconstructed by com-74   Gut and Liver, Vol. 3, No. 2, June 2009
puter generation off-line (Fig. 1). CT colonography has 
the potential advantage of being a rapid and safe method 
of providing full structural evaluation of the entire colon. 
Low sensitivity and specificity and the need for rapid 
high-resolution helical CT scanners originally precluded 
its wide application for routine CRC screening, but soft-
ware and techniques designed to improve the speed, accu-
racy, and reproducibility of results are now available. The 
accuracy and potential of CT colonography as a screening 
tool for colorectal neoplasia has been debated because ini-
tial studies yielded a wide range of sensitivity.
29,30 Two 
recently published trials provide evidence that CT colo-
nography may be a valid alternative for primary colon 
cancer screening. The National CT Colonography Trial
31 
directed by the American College of Radiology Imaging 
Network (ACRIN) was a multicenter study that employed 
CT colonography and same day colonoscopy using a 
standard matching protocol in 2,600 asymptomatic indivi-
duals. Per patient sensitivity of CT colonography for ad-
enomas greater than 10 mm was 90% with a negative 
predictive value of 99%. A second trial
32 compared CT co-
lonography and optical colonoscopy in parallel screening 
cohorts and demonstrated similar rates of detection of ad-
vanced neoplasia in both groups. Several key issues need 
to be addressed as the use of CT colonography becomes 
more widespread, principal among which is determination 
of the acceptable size cut-off of a lesion detected by CT 
colonography that will necessitate a follow-up colono-
scopy. Other issues include the need for bowel prepara-
tion, the logistics of same-day colonoscopy, the ability to 
detect flat lesions, the significance of extracolonic lesions 
detected by CT, and the impact on compliance, and 
cost-effectiveness. Methodologies that employ CT colo-
nography without cathartic preparation and with “fecal 
tagging” may make this a more attractive option for 
screening. CT colonography may also aid in detecting le-
sions located behind folds or near the anal verge.
4. Fecal DNA testing
  A great deal of knowledge has been accumulated re-
cently about genetic alterations that occur during colon 
carcinogenesis, but specific tests are not currently avail-
able for most patients at risk for developing sporadic 
CRC. A molecular approach to CRC screening is attrac-
tive since it targets biologic changes that are fundamental 
to the neoplastic process. The feasibility of detecting al-
tered DNA in stool has been demonstrated using a multi-
target assay panel of molecular markers.
33 One multi-
center study compared fecal DNA testing using such a 
panel with the FOBT and colonoscopy.
34 The fecal DNA 
panel consisted of 21 mutations: 3 in the K-ras gene, 10 
in the APC  gene, 8 in the p53  gene; the MSI marker 
BAT-26; and a marker of long DNA thought to reflect 
disordered apoptosis of cancer cells sloughed into the co-
lonic lumen. Although most of the lesions identified by 
colonoscopy were not detected by either noninvasive test, 
multitargeted fecal DNA testing detected a higher pro-
portion of important lesions compared with Hemoccult. A 
second recently published study
35 compared stool DNA 
and FOBT for detection of “screen-relevant neoplasia” 
(curable stage cancer, high grade dysplasia or adenomas 
＞1 cm). This blinded, multicenter cross sectional study 
used two different methodologies for detecting alterations 
in stool DNA, a 23 marker panel and a new test targeting 
3 broadly informative markers (point mutations on K-ras, 
a scanned mutator cluster region of APC, and methylated 
vimentin. While the multipanel test provided no improve-
ment over FOBT (HemoccultSensa) for detection of 
screen relevant neoplasms, the new test showed promise 
by detecting significantly more neoplasms than FOBT. A 
recently developed digital melting curve assay designed to 
quantify low-abundance mutations in stool samples has 
demonstrated a high sensitivity for detecting individuals 
with colorectal neoplasms in preliminary studies.
36 The 
recent joint guidelines published by American Cancer 
Society, the US Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radiology include 
fecal DNA testing as an option for detecting colorectal 
cancers.
5. Genetic testing in high risk groups
  Genetic testing is now a reality for families with fami-
lial adenomatous polyposis (FAP).
37 Testing for altered 
products of the APC gene allows for early and accurate 
identification of family members at risk who require in-
tensive surveillance (Table 2). Proper genetic counseling, 
however, must be incorporated into the screening process. 
Genetic testing for mutations in the hMSH2 and hMLH1 
genes is appropriate when hereditary nonpolyposis color-
ectal cancer (Lynch Syndrome or HNPCC) is suspected 
but presents more difficulty than screening for FAP, be-
cause not all the genes involved have been identified, and 
the preferred method by which families should be 
screened has yet to be determined.
38 A generally accepted 
approach in individuals suspected of having HNPCC 
based on clinical criteria is first to perform microsatellite 
instability (MSI) testing on the affected individual’s tu-
mor using a panel of microsatellite markers. Germline 
mutation testing for hMLH1 and hMSH2 is performed if 
the tumor is MSI-high (suggesting a mutation in a mis-
match repair gene). In cases in which HNPCC is strongly 
suspected based on clinical criteria, or when a mutation  
Bresalier RS: Early Detection of and Screening for Colorectal Neoplasia   75
Table 2. Guidelines for the Surveillance of Cancer in People at Increased or High Risk
Risk category Age to begin surveillance Recommendation Comment
Increased risk-patients with history of adenomas at prior colonoscopy
  Patients with 1 or 2 small
   t u b u l a r  a d e n o m a s  w i t h 
lowgrade dysplasia
  Patients with 3 to 10
 adenomas or 1 adenoma
 ＞1 cm or any adenoma
 w i t h  v i l l o u s  f e a t u r e s  o r
 high grade dysplasia
  Patients with ＞10 
 adenomas on a single 
 examination
  Patients with sessile
 adenomas that are 
 removed piecemeal
5-10 yr after initial 
 polypolypectomy
3 yr after initial polypectomy
＜3 yr after initial polypectomy
2 to 6 months to verify 
 complete removal
Colonoscopy
Colonoscopy
Colonoscopy
Colonoscopy
Precise timing based on clinical 
 factors, patient and physician 
 preferences
If follow-up exam is normal or 
shows 1 or 2 small tubular 
adenomas, subsequent exam at 
5 yr
Consider familial syndrome
Surveilance individualized based 
 on endoscopist’s judgement
Increased risk-patients with colorectal cancer
  Patients with colon and 
   rectal cancer should 
   u n d e r g o  h i g h - q u a l i t y 
   perioperative clearing
  Patients undergoing curative
   resection for colon or rectal
   c a n c e r
3 to 6 months after cancer 
 resection  or intraoperatively
1 yr after resection (or 1 yr
 after clearing colonoscopy)
Colonoscopy
Colonoscopy
In the case of nonobstructing 
 tumors exam can be done pre-
 operatively; for obstructing 
 cancer CTC or DCBE can be 
 used to detect proximal 
 neoplasms
If exam at 1 yr is normal, 
 subsequent exam at 3 yr. 
 If that exam is normal then 
 subsequent exam at 5 yr. 
Periodic examination of the rectum 
 (3- to 6-month  intervals for the 
 first 2 to 3 years) may be 
 considered after low anterior 
 resection of rectal cancer.
Increased risk-patients with  family history
  Colorectal cancer or
   adenomatous polyps in
   a first-degree relative before
   a g e  6 0  y e a r s  o r  i n  2  o r  m o r e 
   first-degree relatives at any
   a g e
  Either colorectal cancer or
   adenomatous polyps in a 
   firstdegree relative ≥ age 60
   years or in 2 second-degree
   relatives with colorectal 
   c a n c e r
Age 40 or 10 yr before the 
 youngest case in the 
 immediate family
Age 40 yr
Colonoscopy
Screening options at 
 intervals recommended
 for average-risk 
 individuals
Every 5 yr
Screening should begin at an 
 earlier age, but individuals 
 may be screened with any 
 recommended form of testing
is established in a family member, germline testing is 
performed as a first step. If testing for hMLH1 and 
hMSH2 is negative, but HNPCC is strongly suspected, 
germline testing for hMSH6 can be performed. An allele 
of APC designated I1307K
39 is relatively infrequent in the 
general population but common in the Jewish population 
of Ashkenazi descent. There is a modest increase in the 
relative risk for CRC in those with this allele, but the 
penetrance for CRC is low compared with carrier frequen-
cies, and genetic testing for I1307K is not recommended.
APPROACH TO SCREENING
1. Average-risk individuals
  Patients registered in a health care system should be 
categorized according to risk, so that appropriate screen-
ing can be added to other variables of medical evaluation. 
Relative risk should be assessed by family history and by 76   Gut and Liver, Vol. 3, No. 2, June 2009
Table 2. Continued
Risk category Age to begin surveillance Recommendation Comment
High risk
  Genetic diagnosis of FAP or 
 suspected FAP without genetic 
 testing evidence
  Genetic or clinical diagnosis of 
   H N P C C  o r  i n d i v i d u a l s
   at increased risk of HNPCC
  Inflamatory bowel disease 
   (chronic ulcerative colitis, and 
   C r o h n ’ s  c o l i t s )
Age 10 to 12 yr
Age 20 to 25 yr or 10 yr 
 before the youngest case 
 in the immediate family
Cancer risk begins to be 
 significant 8 yr after the 
 onset of pancolitis or 
 12 to 15 yr after the
 onset of left-sided colitis
Annual FSIG to 
 determine if the 
 individual is expressing
 the genetic abnormality 
 and counseling to 
 consider genetic testing
Colonoscopy every 1 to 2
 yr and counseling to 
 consider genetic testing
Colonoscopy with 
 biopsies for dysplasia
If the genetic test is positive, 
 coloectomy should be considered
Genetic testing for HNPCC should 
 be offered to first-degree relatives 
 of persons with a known 
 inherited MMR gene mutation. It
 should also be offered when the 
 family mutation is not known but 
 1 of the first 3 of the modified 
 Bethesda Criteria is present.
Every 1 to 2 yr; these patients are 
 best referred to a center with 
 experience in the surveillance and 
 management of inflammatory 
 bowel disease.
CTC, computed tomographic colonography; DCBE, double contrast barium enema; FAP, familial adenomatous polyposis; HNPCC, 
hereditary nonpolyposis colorectal cancer; FSIG, flexible sigmoidoscopy; MMR, mismatch repair. 
Derived from Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and 
adenomatous polyps 2008: a joint guideline from the American Cancer Society, the Multi-Society Task Force on colorectal cancer 
and the American College of Radiology. CA Cancer J Clin 2008;58:130-160.
personal history using questionnaires. A variety of op-
tions are available for screening average-risk individuals 
(≥50 years of age with no personal or family history of 
colorectal adenoma or carcinoma, and no personal history 
of inflammatory bowel disease). Current guidelines for 
screening average risk individuals have already been dis-
cussed and the joint guidelines recently set forth by the 
American Cancer Society, US Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology 
as well as recently published guidelines from the USPSTF 
are presented in Table 1.
  National and regional colorectal cancer screening pro-
grams have recently been adopted by several countries in-
cluding Canada (Ontario 2007), countries in the 
European Union, and in some Asian countries. In the 
Rupublic of Korea, for example, CRC screening has been 
part of a national cancer screening program since 2004. 
A n n u a l  F O B T  ( i m m u n o c h e m i c a l  o r  H e m o q u a n t )  i s  o f -
fered to individuals ages 50 and higher. Double contrast 
barium enema and/or colonoscopy are used to follow up 
positive FOBTs. The total target is 4.4 million, and the 
screening rate was about 16% in 2006. The screening 
program is free of charge. An inventory of colorectal can-
cer screening activities in 25 countries comprising the 
International Cancer Screening Network (sponsored by 
t h e  U S  n a t i o n a l  C a n c e r  I n s t i t u t e )  w a s  p u b l i s h e d  i n  M a y  
2008.
40 The primary modality for screening varies be-
tween countries, and depends on health care resources 
and availability of manpower and expertise for various 
methods.
2. Individuals at increased risk for colorectal can-
cer 
1) Personal or family history of colorectal ad-
enoma
  Table 2 lists the updated (2008) ACS/Multi-Society/ 
ACR guidelines for screening, surveillance, and early de-
tection of colorectal adenomas and cancer for individuals 
a t  i n c r e a s e d  r i s k  o r  a t  h i g h  r i s k  o f  d i s e a s e  T h e s e  g u i d e -
lines suggests that those whose index lesion consists of 1 
or 2 small tubular adenomas with low grade dysplasia 
should have a follow-up colonoscopy 5 to 10 years after 
the initial polypectomy. The precise timing within this in-
terval should be based on clinical factors (prior findings, 
family history, patient and physician preferences). One re-
cent study examined the relative risk for advanced neo-
plasia within 5.5 years of a baseline colonoscopy.
41 There 
was a strong association between the results of baseline 
screening colonoscopy and the rate of serious incident le- 
Bresalier RS: Early Detection of and Screening for Colorectal Neoplasia   77
sions during surveillance. This study confirmed that pa-
tients with 1 or 2 small tubular adenomas represent a 
low risk group compared with other patients with color-
ectal neoplasia. In those with a large (＞1 cm) adenoma, 
multiple (3 to 10) adenomas, or adenomas with high- 
grade dysplasia or villous change, colonoscopy should be 
repeated within 3 years after the initial polypectomy. 
Although the risk for recurrence of advanced adenomas at 
this follow up interval is greater in patients with high 
risk adenomas than those with low risk adenomas, the 
incremental risk is small.
42 If the exam is normal or 
shows only 1 or 2 small tubular adenoms with low grade 
dysplasia, then the interval for the subsequent exam 
should be 5 years. Patients with ＞10 adenomas on a sin-
gle examination should have a follow up colonoscopy less 
than 3 years after the initial polypectomy and the pres-
e n c e  o f  a n  u n d e r l y i n g  f a m i l i a l  s y n d r o m e  s h o u l d  b e  
considered. Patients with sessile adenomas that are re-
moved piecemeal should have follow up colonoscopy in 2 
to 6 months to verify complete removal. 
2) Individuals with a personal history of colorectal 
cancer 
  Patients with colon or rectal cancer should have high 
quality perioperative clearing. Colonoscopy should be per-
formed preoperatively, by intraoperative colonoscopy, or 
within 3 to 6 months after cancer resection. Those who 
have had a colon cancer resected should have colonoscopy 
performed one year after surgery or the original clearing 
colonoscopy. If the examination performed at one year is 
normal, then the interval before the next colonoscopy 
should be 3 years, then (if normal) at 5 years (Table 2). 
Periodic examination of the rectum for the purposes of 
identifying local recurrence is usually performed at 3- to 
6-month intervals for the first 2 or 3 years after low ante-
rior resection for rectal cancer. Serum CEA levels should 
be measured at regular intervals because postoperative 
CEA determinations may be cost-effective for detecting 
recurrent cancers. How long an asymptomatic patient 
who has had multiple negative examinations should be 
tested by various modalities is at present unclear. It 
should be noted that these recommendations are to some 
extent “educated guesses”, and not all are based on pro-
spective, randomized trials. 
3. High-risk groups
1) Familial adenomatous polyposis and familial 
cancer
  Screening should include genetic testing to detect ab-
normal (truncated) APC gene products if a diagnosis can 
be made by this method in one family member. Those 
who test positive should have annual or biannual FS, be-
ginning at age 10-12 years, to assess for emergence of ad-
enomas and to plan appropriate timing for colectomy. If 
genetic testing is unavailable, annual FS should begin at 
age 10 to 12 years. Genetic testing should always be com-
bined with education and counseling of the individual as 
well as family members. Colorectal surveillance (sigmoi-
doscopy) should begin at age 18 to 20 in individuals with 
attenuated FAP (AFAP) and in individuals with MUTYH 
mutations (here colonoscopy is recommended).
  Patients with a family history of HNPCC must be ex-
amined colonoscopically, beginning at age 20 to 25 years, 
or at an age 10 years younger than that of the index case, 
because one cannot rely only on the FOBT in these very- 
high-risk patients. A reasonable approach is to perform 
colonoscopy every 2 years. The search is primarily for the 
scattered adenomas that antedate carcinomas in these 
syndromes. Genetic testing for HNPCC should be offered 
to first-degree relatives of those with a known mismatch 
repair gene mutation, or in those who meet the modified 
Bethesda criteria for HNPCC.
38 Genetic testing should be 
accompanied by counseling of the individual and the fam-
ily members. The benefits of colonoscopic surveillance in 
patients with HNPCC mutations are suggested by screen-
ing trials.
43
  The approach to patients with a suggestive family his-
tory (e.g., one first-degree relative with colon cancer) is 
not firmly established, but existing data suggest that 
these patients should be monitored more rigorously than 
average-risk individuals. The joint guidelines from the 
ACS and US Multi-Society Task Force on Colorectal 
Cancer recommend that if CRC or adenomatous polyps 
occurred in any first-degree relative before age 60 years, 
o r  i n  t w o  o r  m o r e  f i r s t - d e g r e e  r e l a t i v e s  a t  a n y  a g e ,  t h e n 
colonoscopy should be performed every 5 years, beginning 
a t  a g e  4 0  y e a r s ,  o r  1 0  y e a r s  b e f o r e  t h e  y o u n g e s t  c a s e  i n 
the immediate family. If either colorectal cancer or ad-
enomatous polyps occurred in a first degree relative 60 
years of age or older, or colorectal cancer occuureed in 2 
second degree relatives, then screening should begin at 
age 40 using screening options recommended for aver-
age-risk individuals. In those with more than two affected 
first-degree relatives, special care should be taken to ex-
clude the diagnosis of HNPCC, and periodic colonoscopy 
is advised.
2) Inflammatory bowel disease
  Colorectal cancer arising in the setting of inflammatory 
bowel disease (ulcerative colitis, Crohn’s disease) was re-
cently reviewed in this journal.
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lance schedule for patients with IBD has not been de-
termined in long-term prospective trials. Colonoscopy 
combined with mucosal biopsy may be effective in detect-
ing preneoplastic and early neoplastic lesions in patients 
with UC. The current recommendation is for colonoscopy 
every 1 or 2 years for patients who have had universal 
colitis for 8 years or left-sided UC for 12 to 15 years. 
B i o p s i e s  s h o u l d  b e  t a k e n  t h r o u g h o u t  t h e  c o l o n  a t  1 0 - c m 
intervals, with special attention to areas that suggest a 
dysplasia-associated mass lesion (DALM). Although this 
biopsy procedure enables histology of only a small area of 
the colon, the short-term risk of carcinoma for patients 
with a negative biopsy is low. If dysplasia is high-grade or 
associated with a macroscopic lesion or mass, colectomy 
is recommended. A histologic diagnosis of low-grade dys-
plasia merits endoscopic follow-up at short intervals (e.g., 
at 3 to 6 months) as does an “indeterminate” reading re-
sulting from active inflammation. Colectomy has been ad-
vocated by some for confirmed low-grade dysplasia. Pa-
tients with Crohn’s disease of the colon should be eval-
uated endoscopically as dictated by symptoms, and special 
attention should be paid to strictured areas. Studies sug-
gest a role for surveillance colonoscopy.
45
QUALITY ASSURANCE
  Colonoscopy is now the most common endoscopic pro-
cedure performed in the United States. Guidelines and 
screening programs in many countries recommend colo-
noscopy as a follow-up to positive screening FOBTs. As 
the number of colonoscopies (and colonoscopists) in-
creases, quality assurance measures will need to be 
adopted. One measure of quality assurance relates to ad-
equate visualization of the colonic mucosa. One study 
from a community based practice in the US
46 suggests 
that detection of overall and advanced neoplasia may be 
related to withdrawal time during colonoscopy. After im-
plementing a protocol of inspection during a minimum 
withdrawal time of 8 minutes, greater rates of detection 
were observed. Others, while agreeing that adequate visu-
alization of the mucosa is an important quality assurance 
parameter, have suggested that adequate exams relate to 
the experience and quality of the endosocopist and not 
withdrawal time per se. A “Physician Performance Mea-
surement Set” for endoscopy and surveillance has been 
proposed in a joint document by the American Society for 
Gastrointestinal Endoscopy, the American Gastroentero-
logical Association, the Physician Consortium for Perfor-
mance Improvement, and the National Committee for 
Quality Assurance. 
1. Future directions
  W h i l e  c o n s i d e r a b l e  p r o g r e s s  h a s  b e e n  m a d e  i n  u n d e r -
standing the molecular biology and natural history of col-
orectal cancer and how this may impact preventive meas-
ures, implementation of patient friendly and cost-effective 
CRC screening efforts remains a global problem. CRC is 
curable when detected in its early stages, yet at best one 
third of cancers when diagnosed are considered early 
cancers. Far less than one half of individuals who meet 
established guidelines for screening actually undergo CRC 
screening. The cost-effectiveness of any screening program 
is highly dependent on adequate compliance. Compliance 
with screening recommendations and optimal utilization 
of resources, both financial and with respect to man-
power, are issues which need to be resolved.
  Efforts at primary prevention of CRC through chemo-
prevention have been somewhat successful,
4 but not es-
tablished for clinical practice except in high-risk groups. 
While it is unlikely that chemoprevention will make 
screening unnecessary, successful efforts at primary pre-
vention may lead to fewer and safer screening exams. 
Current guidelines for screening and surveillance for col-
orectal neoplasia have recognized the importance of risk 
stratification in determining proper screening intervals for 
both average risk individuals and those at higher risk. 
Proper risk stratification and compliance with guidelines 
based on these efforts will be key to developing cost-ef-
fective models for CRC screening. Development of sensi-
tive and specific noninvasive screening tests for CRC is a 
high priority for population-based screening programs. 
Radiographic techniques such as CT colonography may 
prove effective for screening average-risk individuals, but 
proper and cost-effective follow-up of those in whom le-
sions are found need to be adequately defined. Colono-
scopy, while sensitive and specific, is impractical for pop-
ulation screening in many countries.
11,12,40 Screening 
methods based on the biology of cancers such as stool 
DNA testing or serum-based methods for specific tu-
mor-associated markers are actively being developed and 
are eagerly awaited.
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